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ABSTRACT  
 
Introduction: High blood pressure (BP), pulse pressure (PP), and rate pressure 
product (RPP) are each associated independently with a poor outcome in acute 
ischaemic stroke. While nitric oxide (NO) donors such as glyceryl trinitrate (GTN) 
lower blood pressure in acute ischaemic stroke, their effect on other 
haemodynamic measures is not known.  
 
Methods: We performed a systematic review of the effects of NO donors on 
systemic haemodynamic measures in patients with acute/subacute stroke. 
Randomised controlled trials were identified from searches of the Cochrane 
Library, Pubmed and Embase. Information on haemodynamic measures were 
assessed, including systolic and diastolic BP and heart rate; haemodynamic 
derivatives of these were calculated: pulse pressure (PP=SBP-DBP), mean 
arterial pressure (MAP=DBP+PP/3), mid blood pressure (MBP=(SBP+DBP)/2), 
pulse pressure index (PPI=PP/MAP), and rate pressure product (RPP=SBPxHR). 
The effect of treatment on haemodynamic measures was calculated as the 
weighted mean difference (WMD) between treated and control groups with 
adjustment for baseline.  
 
Results: Three trials involving 145 patients were identified; 93 patients received 
the NO donor, GTN, and 52 control. As compared with placebo, GTN significantly 
reduced SBP (WMD -9.80 mmHg, p< 0.001), DBP (WMD –4.43 mmHg, p< 
0.001), MAP (WMD –6.41 mmHg, p< 0.001), MBP (WMD –7.33 mmHg, 
p<0.001), PP (WMD –6.11 mmHg, p<0.001 ) and PPI (WMD –0.03, p=0.04 ). 
3 
GTN increased HR (WMD +3.87 bpm, p<0.001) and non-significantly lowered 
RPP (WMD –323 mmHg.bpm, p=0.14).  
 
Conclusion: The NO donor GTN reduces BP, PP and other derivatives in acute and 
subacute stroke whilst increasing heart rate.  
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INTRODUCTION 
 
High blood pressure (BP), a key risk factor for the development of 
cerebrovascular disease, is common in acute ischaemic and haemorrhagic stroke, 
and is associated independently with increased death or dependency.[1] A 
number of haemodynamic measures can be derived directly from blood pressure 
and heart rate, and may provide additional prognostic information in stroke. 
These include pulse pressure (PP), the difference between systolic blood pressure 
(SBP) and diastolic blood pressure (DBP); mean arterial pressure (MAP); mid 
blood pressure (MBP), which may be a better predictor of cardiovascular events 
than either SBP or DBP alone;[2] and rate pressure product (RPP), an index of 
myocardial work load. Each of these measures is associated independently with a 
poor outcome (as measured by death or dependency) in ischaemic stroke.[3] An 
increased heart rate (HR) may also be associated with a poor outcome.[4, 5] 
 
Since high BP is associated with a poor functional outcome, several large 
randomised controlled trials [6-8] are now studying whether lowering BP might 
improve functional outcome. However, the effect of the various antihypertensive 
agents on other haemodynamic measures has not been reported. 
 
Nitric oxide (NO), a neurotransmitter with vasoactive properties, is a regulator of 
blood pressure, cerebral blood flow (CBF) and tissue perfusion.[9] In 
experimental stroke, nitric oxide donors are neuroprotective, reduce infarct 
volume  and modulate CBF;[10] as such NO donors are a candidate treatment 
for acute stroke. Several small trials of NO donors in patients with recent stroke 
have been published and found that NO, given as GTN, lowered systolic BP. [11-
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14] However, the effect of NO donors on these derived haemodynamic measures 
has not been reported. We performed a systematic review of the effect of NO 
donors on systemic haemodynamic measures in patients with acute/subacute 
stroke. 
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METHODS 
 
Trials and data 
Completed non-confounded randomised controlled trials of NO donors in 
acute/sub acute stroke (randomisation within one week of stroke) were identified 
from searches of The Cochrane Library, PubMed and Embase. The search 
included articles up to May 2006 and employed three primary search terms 
(glyceryl trinitrate, stroke and trial). Additional trials were identified through 
searches of non-systematic reviews and reference lists. The searches were 
limited to human studies reported in English. Individual patient data were sought 
for each included trial. Study quality was assessed across five domains: method 
of randomisation, blinding to treatment, reporting of withdrawals, generation of 
random numbers and allocation concealment. Trials scored one point for each 
area addressed, therefore receiving a score between 0-5, with 5 reflecting the 
highest level of quality.[15] 
 
Haemodynamic measures 
Data on the method of BP measurement, systolic (SBP) and diastolic (DBP) BP, 
and heart rate (HR) were identified for measurements made at baseline and 
following treatment with the NO donor or control therapy. Derivative 
haemodynamic measures were calculated as follows: pulse pressure (PP=SBP-
DBP), mean arterial pressure (MAP=DBP+PP/3), mid blood pressure 
(MBP=(SBP+DBP)/2), pulse pressure index (PPI=PP/MAP), and rate pressure 
product (RPP=SBP*HR). 
 
Statistical methods 
Data were analysed using the Cochrane RevMan software [16] and Stata (version 
7 
7).[17] Individual patient data were analysed on treatment with adjustment for 
baseline measures by analysis of covariance. The difference in measurements 
between patients randomised to NO donor and control is expressed as the 
weighted mean difference (WMD, with 95% confidence intervals), calculated 
using a random effects model. Statistical heterogeneity was assessed using a χ2 
test. 
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RESULTS 
 
Trial characteristics 
Three completed randomised controlled trials of NO donors in acute/subacute 
stroke were identified.[11-13] A non randomised comparison of intravenous 
sodium nitroprusside in patients with acute ischaemic stroke and normal older 
volunteers was excluded.[18] The trials included a total of 145 patients (NO 
donor 93, control 52) and each assessed transdermal glyceryl trinitrate (GTN), 
an organic nitrate. Each trial was randomised and treatment allocation was 
concealed; one trial was double-blind placebo controlled [11] and the other two 
single-blind (table 1).[12, 13] All three trials included patients with either 
ischaemic stroke or primary intracerebral haemorrhage. Patients were enrolled 
within 75 hours of stroke onset (table 1). 
 
Two trials studied GTN given at a dose of 5 mg,[11, 13] the other had three 
active arms with GTN used at (i) 5mg for 10 days; (ii) 5mg for 4 days followed 
by 10mg for 6 days; and (iii) 10mg for 10 days (table 1). To allow for this 
difference in doses, the data from this trial were separated into two, patients 
receiving 5mg or 5mg followed by 10mg (the increased dose was started at day 
4 and therefore will not have affected BP measurements at baseline or after first 
dosing) and those receiving 10mg for the duration of the trial. Two trials used 24 
hour ambulatory blood pressure monitoring,[11, 12] whereas one reported BP 
using a validated digital readout oscillometric device (Omron 705CP) at 1-2 hours 
post treatment.[13] Use of automated BP monitors means readings were 
effectively made blinded to treatment allocation. 
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Patient characteristics 
Patients across the three trials have similar ages and types of presenting stroke. 
The trial of Willmot et al had a lower proportion of males and patients with 
cortical stroke, and the trial of Bath et al had a higher proportion of patients with 
a history of hypertension (table 2).  
 
NO donors on haemodynamic measures 
GTN significantly reduced SBP (WMD -9.8 mmHg), DBP (WMD –4.4 mmHg), MAP 
(-6.4 mmHg), MBP (-7.3 mmHg), PP (-6.1) and PPI (-0.03) (table 3, figures 1A-
C); additionally, GTN non-significantly reduced RPP (table 3). In contrast, GTN 
increased HR (WMD +3.9 bpm) (table 3). No heterogeneity in measures was 
observed between trials. 
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DISCUSSION 
 
This systematic review has found that the NO donor, GTN, reduces a variety of 
systemic haemodynamic measures including systolic BP, diastolic BP, mean 
arterial BP, mid blood pressure, pulse pressure and pulse pressure index in 
patients with acute/subacute stroke. GTN increased heart rate but tended to 
reduce rate pressure product, presumably representing a balance between 
decreasing BP, and modestly increasing heart rate. The non significant reduction 
in RPP suggests that GTN may tend to reduce myocardial work. 
 
As these haemodynamic measures are associated independently with a poor 
outcome, [1, 3] so that there reduction (apart from HR) might improve functional 
outcome after stroke. Several trials are assessing lowering BP in patients with 
acute stroke with a variety of drugs including candesartan (angiotensin receptor 
antagonist, SCAST [6]), GTN (ENOS [7]), labetalol (ß-receptor antagonist, 
CHHIPS [8]), and lisinopril (angiotensin converting enzyme inhibitor, CHHIPS 
[8]); another study is using a variety of agents as chosen by the local 
investigator (INTERACT[19]). However, only one small trial has reported the 
effect of any of these antihypertensive agents on BP derived haemodynamic 
measures.[12] Previous studies have suggested that some BP lowering 
approaches may be detrimental such as atenolol/propranolol (ß-receptor 
antagonists) and nimodipine (dihydropyridine calcium antagonist).[20-22] 
Hence, the class of antihypertensive agent may be important when considering 
how to lower BP in acute stroke.[23] 
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BP measurements were automated in the three studies and therefore were 
effectively made blinded to treatment assignment. However, they were not 
standardised [24] in respect of the measurement technique; one trial used office 
measurements made 1-2 hours post first treatment therefore reflecting peak BP 
lowering effects;[13] in contrast, the other two studies relied on 24 hour 
ambulatory BP monitoring.[11, 12] Although ambulatory BP monitoring is a good 
predictor of outcome in acute stroke,[25] it measures average rather than peak 
haemodynamic effects; as such the upper limit of ‘normal’ for each vary (office ≤ 
135/85, ABPM ≤ 130/80).[26] Hence, the weighted mean difference in 
haemodynamic measures reported here are a mix of peak and average effects, 
so the findings are robust to measurement variations and the effects of GTN may 
be underestimated. 
 
The identified trials of GTN were all small (18-90 subjects) and could not assess 
the effect of GTN on functional outcome; this is being investigated in the ongoing 
‘Efficacy of Nitric Oxide in Stroke’ (ENOS) trial.[7] 
 
CONCLUSION 
 
In summary, GTN reduces haemodynamic measures known to be related to poor 
prognosis in patients with acute/subacute stroke and as such is a suitable 
candidate agent for testing whether BP should be lowered in patients with acute 
stroke. 
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TABLE 1 
Characteristics of included trials 
Trial Dose Active 
n 
Control 
n 
Mean time, stroke-
enrolment (hours) 
BP 
Timing 
BP Method Primary 
outcome 
Quality 
score (/5) 
Bath 
[11] 
GTN 5mg 16 21 99.6 Baseline 
Day 1 
ABPM 
Spacelabs 
Blood 
pressure 
5 
Rashid 
[12] 
GTN 5mg/ GTN 
5/10mg/GTN 10mg 
20/20/20 30 54.4 Baseline 
Day 1 
ABPM 
Spacelabs 
24 hour MAP 4 
Willmot 
[13] 
GTN 5mg 12 6 72.2 Baseline 
1 hour  
Omron 
705CP 
Cerebral 
blood flow 
4 
 
17 
TABLE 2 
Characteristics of included patients in each trial. Mean (standard deviation) or % 
Characteristic Bath [11] Rashid [12] Willmot [13] 
Number of patients 37 90 18 
Age (years) 73.7 (9.1) 71.8 (11.8) 69.4 (7.4) 
Gender, male (%) 48.6 45.6 27.8 
History of hypertension (%) 62.2 40.0 38.9 
Ischeamic stroke (%) 89.2 93.3 88.9 
Cortical syndrome (%) 54.1 53.3 33.3 
Scandinavian stroke scale (/58) - 32.6 (11.7) 42.1 (10.5) 
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TABLE 3 
 
Effect of first dose of NO donor on haemodynamic measures in 145 patients (All measures adjusted for baseline value) 
Outcome Comparisons Control group  
mean 
WMD 95% CI p value Heterogeneity p value 
Systolic blood pressure 4 161.1 -9.8 -12.9, -6.7 <0.0001 0.50 
Diastolic blood pressure 4 88.4 -4.4 -6.4, -2.5 <0.0001 1.00 
Heart rate 4 72.9 3.9 1.7, 6.1 0.001 0.91 
Mean arterial pressure 4 112.8 -6.4 -8.5, -4.3 <0.0001 0.86 
Mid blood pressure 4 124.9 -7.3 -9.6, -5.0 <0.0001 0.69 
Pulse pressure 4 73.7 -6.1 -9.4, -2.8 0.0003 0.11 
Pulse pressure index 4 0.66 -0.03 -0.06, 0.00 0.04 0.07 
Rate pressure product 4 11768 -323 -746, 101 0.14 0.87 
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TITLES AND LEGENDS TO FIGURES 
FIGURE 1 
A) Forest plot of effect of NO donors on systolic blood pressure; weighted mean difference 
 
FIGURE 1 
B) Forest plot of effect of NO donors on diastolic blood pressure; weighted mean difference 
 
FIGURE 1 
C) Forest plot of effect of NO donors on pulse pressure; weighted mean difference 
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FIGURE 1 
A) Forest plot of effect of NO donors on systolic blood pressure; weighted mean difference 
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FIGURE 1 
B) Forest plot of effect of NO donors on diastolic blood pressure; weighted mean difference 
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FIGURE 1 
C) Forest plot of effect of NO donors on pulse pressure; weighted mean difference 
 
 
 
 
